Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111605 · ClinicalTrials.gov registry record · Phase 1
Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
NCT00111605 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 144 participants.
The verdict
NCT00111605, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of an experimental HIV vaccine. The vaccine will be given with or without IL-12 DNA adjuvant (at three escalating doses of 100, 500, and 1,500 mcg respectively), a substance that helps the body respond to a vaccine. This study will also determine the safety and tolerability of an experimental HIV vaccine boosted with two adjuvants.
Interventions
- BIOLOGICAL HIV-1 gag DNA
- BIOLOGICAL HIV-1 gag DNA plus IL-12 DNA adjuvant
- BIOLOGICAL CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)
- BIOLOGICAL Sodium chloride injection (0.9%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111605
The ClinicalTrials.gov registry entry for NCT00111605 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which HIV-1 gag DNA is the first listed.
NCT00111605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111605 about?
NCT00111605 is a clinical study titled "Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults". The purpose of this study is to evaluate the safety and tolerability of an experimental HIV vaccine. The vaccine will be given with or without IL-12 DNA adjuvant (at three escalating doses of 100, 500, and 1,500 mcg respectively), a substance that helps the body respond to a vaccine. This study will...
What is the current status of trial NCT00111605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00111605?
The interventions under investigation include: HIV-1 gag DNA (BIOLOGICAL), HIV-1 gag DNA plus IL-12 DNA adjuvant (BIOLOGICAL), CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine) (BIOLOGICAL), Sodium chloride injection (0.9%) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00111605?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.